Background Premature cardiovascular events had been observed in Systemic Lupus Erythematosus (SLE) patients,  but the reason for this accelerated process is still debatable.  One of the most important conditions, is a proatherogenic lipid profile.  In SLE mexicans we do not have enough data about it.
Objectives To establish the differences in the lipid profiles between Mexican SLE patients and general population.
Methods Observational, transversal, descriptive and comparative study, between SLE patients and age-sex- matched healthy volunteers. Ethical approved (MI09-007). Full lipid profile (by spectrophotometry) after 14 hours- fast were performed. Total value of cholesterol (LDL, HDL) and triglycerides were analyzed. We also, realized, a sub-analysis, with proaterogenic values of cholesterol (Total cholesterol >200 mg/dl, triglycerides >150 mg/dl, HDL-cholesterol < 45 mg/dl and LDL-cholesterol >100 mg/dl). Results were analyzed by the statistical package SPSS v.17.
Results 138 full lipid profiles of different subjects were analyzed; 69 with diagnosis of SLE and 69 age-sex healthy volunteers. The main demographic characteristics are detailed in Table 1. We found statistically significant differences between the mean of total cholesterol and LDL. In a posterior sub-analysis did not found significant differences. We detailed the biochemical parameters in Table 2.
Conclusions We did not found statistical differences in the lipid profiles explaining an increased cardiovascular morbi-mortality in SLE patients compared to healthy volunteers.
Thomas GN, Tam LS, Tomlinson B, Li EK. Accelerated atherosclerosis in patients with systemic lupus erythematosus: a review of the causes and possible prevention. Hong Kong Med J. 2002 Feb;8(1):26-32.
Bruce IN.’Not only…but also’: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford).2005 Dec;44(12):1492-502.
Leong KH, Koh ET, Feng PH, Boey ML. Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol 1994; 21(7): 1264-7
Disclosure of Interest None Declared